Extended-release naltrexone/bupropion is safe and effective among subjects with type 2 diabetes already taking incretin agents: a post-hoc analysis of the LIGHT trial

BACKGROUND: Extended-release naltrexone/bupropion (NB) is indicated for chronic weight management. Incretin agents are recommended for patients with type 2 diabetes. This analysis looked at the add-on of NB to incretins to see if weight loss could occur in patients already stabilized on incretin age...

Descripción completa

Detalles Bibliográficos
Autores principales: Wharton, Sean, Yin, Peter, Burrows, Melonie, Gould, Errol, Blavignac, Jessica, Christensen, Rebecca A. G., Kamran, Elham, Camacho, Fernando, Barakat, Maxime
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8310797/
https://www.ncbi.nlm.nih.gov/pubmed/34083744
http://dx.doi.org/10.1038/s41366-021-00831-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8310797/
https://www.ncbi.nlm.nih.gov/pubmed/34083744
http://dx.doi.org/10.1038/s41366-021-00831-4

Ejemplares similares